Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
Company profile
Ticker
ADMS
Exchange
Website
CEO
Neil McFarlane
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NeuroMolecular Pharmaceuticals Inc
SEC CIK
Corporate docs
Subsidiaries
Adamas Pharma, LLC ...
ADMS stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
6 Dec 21
EFFECT
Notice of effectiveness
2 Dec 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
Transcripts
ADMS
Earnings call transcript
2021 Q2
10 Aug 21
ADMS
Earnings call transcript
2021 Q1
11 May 21
ADMS
Earnings call transcript
2020 Q4
24 Feb 21
ADMS
Earnings call transcript
2020 Q3
8 Nov 20
ADMS
Earnings call transcript
2020 Q2
6 Aug 20
ADMS
Earnings call transcript
2020 Q1
9 May 20
ADMS
Earnings call transcript
2019 Q4
25 Feb 20
ADMS
Earnings call transcript
2019 Q3
7 Nov 19
ADMS
Earnings call transcript
2019 Q2
8 Aug 19
ADMS
Earnings call transcript
2019 Q1
9 May 19
Latest ownership filings
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 22
SC 13G/A
Stonepine Capital Management, LLC
14 Feb 22
SC 13G/A
Opaleye Management Inc.
26 Jan 22
SC 13G/A
FMR LLC
10 Dec 21
4
MICHAEL BIGHAM
24 Nov 21
4
DAVID L MAHONEY
24 Nov 21
4
Neil F. McFarlane
24 Nov 21
4
Christopher B Prentiss
24 Nov 21
4
William W. Ericson
24 Nov 21
4
Vijay Shreedhar
24 Nov 21
Financial summary
Quarter (USD) | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 78.62 mm | 78.62 mm | 78.62 mm | 78.62 mm | 78.62 mm | 78.62 mm |
Cash burn (monthly) | 3.39 mm | (no burn) | 1.88 mm | 3.27 mm | 2.08 mm | 3.90 mm |
Cash used (since last report) | 103.99 mm | n/a | 57.60 mm | 100.40 mm | 63.83 mm | 119.62 mm |
Cash remaining | -25.36 mm | n/a | 21.02 mm | -21.78 mm | 14.79 mm | -40.99 mm |
Runway (months of cash) | -7.5 | n/a | 11.2 | -6.7 | 7.1 | -10.5 |
Institutional ownership, Q4 2021
7.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 1 |
Closed positions | 60 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 25.77 mm |
Total shares | 3.23 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Magnetar Financial | 3.13 mm | $25.28 mm |
Healthcare Value Capital | 100.00 k | $491.00 k |
Hirschman Orin | 0.00 | $0.00 |
Stonepine Capital Management | 0.00 | $0.00 |
Armistice Capital | 0.00 | $0.00 |